Press release from Companies
Published: 2016-09-05 08:24:08
WntResearch today announced that the company has entered into an agreement with Recall Capital regarding the share trade service Q2Trade™. This is done to reduce market risks and stimulate to a more stable trade of the company’s stock.
Q2Trade™ is a strictly mathematical model based on historical stock trade information and is used to achieve a more stable trade on the stock market. For further information contact: About WntResearch WntResearch’s most advanced drug candidate Foxy-5 has in preclinical tests been shown to reduce tumour cells’ mobility and thereby counteract the occurrence of metastasis. The results from a completed phase 1-study show a favourable security profile and pharmacokinetics as well as early indications of biological activity. A phase 1b-study is currently ongoing in patients with cancer in colon, prostate and breast. WntResearch is a public company listed at AktieTorget in Stockholm, Sweden. For further information: www.wntresearch.com
Henrik Lawaetz, CEO
E-mail: hl@wntresearch.com
Telephone: +46 72 702 4694
WntResearch is developing a new type of cancer treatment based on pioneering research, which shows that the endogenous protein Wnt-5a plays a crucial role for tumour cells’ ability to relocate and spread inside the body. Most patients that die of cancer do so not due to the primary tumour, but due to metastasises and the need for a specific treatment to counteract metastasis is therefore in high demand.
